Nu-Med Plus, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Nu-Med Plus, Inc. has filed its 2023 annual report, detailing its operations and financial status.</b>

AI Summary

Nu-Med Plus, Inc. (NUMD) filed a Annual Report (10-K) with the SEC on March 26, 2024. Nu-Med Plus, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is registered in Utah and its principal executive offices are located in Port Jefferson, NY. Nu-Med Plus, Inc. is classified under SIC code 3841 for Surgical & Medical Instruments & Apparatus. The company has submitted and posted all Interactive Data Files required by Rule 405 of Regulation S-T. Nu-Med Plus, Inc. is not a well-known seasoned issuer, an accelerated filer, or a large accelerated filer.

Why It Matters

For investors and stakeholders tracking Nu-Med Plus, Inc., this filing contains several important signals. This filing provides a comprehensive overview of Nu-Med Plus, Inc.'s performance and compliance for the fiscal year 2023. As a smaller reporting company, this 10-K is crucial for investors to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: low — Nu-Med Plus, Inc. shows low risk based on this filing. The filing indicates Nu-Med Plus, Inc. is a smaller reporting company and not a well-known seasoned issuer, suggesting limited market visibility and potentially less robust financial disclosures compared to larger entities.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements and risk factors to understand Nu-Med Plus, Inc.'s current operational status and future prospects.

Key Numbers

• 2023-12-31 — Fiscal Year End (Annual report for the year ended December 31, 2023)
• 2024-03-26 — Filing Date (Date the 10-K was filed)
• 000-54808 — Commission File Number (SEC Commission File Number for Nu-Med Plus, Inc.)
• 3841 — SIC Code (Standard Industrial Classification code for Surgical & Medical Instruments & Apparatus)

Key Players & Entities

• Nu-Med Plus, Inc. (company) — Filer name and company name
• NUMD (company) — Ticker symbol
• 2023-12-31 (date) — Fiscal year end date
• 2024-03-26 (date) — Filing date
• 3841 (industry_code) — Standard Industrial Classification code
• UT (location) — State of incorporation
• Port Jefferson (location) — Principal executive offices city
• 45-3672530 (tax_id) — IRS Employer I.D. No.

FAQ

Risk Factors

• Reporting Requirements [medium — regulatory]: The company is subject to various reporting requirements under the Securities Exchange Act of 1934.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-03-26: 10-K Filing Date — Date Nu-Med Plus, Inc. submitted its annual report.

Key Financial Figures

• $0.0169 — pany's last sale price of its stock was $0.0169 resulting in an aggregate market value
• $1.0 billion — ("JOBS ACT"), companies with less than $1.0 billion in gross revenue can qualify as an "eme
• $700.0 million — that are held by non-affiliates exceeds $700.0 million as of the last business day of our most
• $30,000 — oxide delivery system is approximately $30,000 each. Market expansion in the US will o

Filing Documents

• numd-20231231.htm (10-K) — 446KB
• ex31-1.htm (EX-31) — 8KB
• ex31-2.htm (EX-31) — 7KB
• ex32.htm (EX-32) — 4KB
• image_001.gif (GRAPHIC) — 3KB
• 0001548123-24-000025.txt (&nbsp;) — 2585KB
• numd-20231231.xsd (EX-101.SCH) — 29KB
• numd-20231231_cal.xml (EX-101.CAL) — 26KB
• numd-20231231_pre.xml (EX-101.PRE) — 111KB
• numd-20231231_def.xml (EX-101.DEF) — 117KB
• numd-20231231_lab.xml (EX-101.LAB) — 205KB
• numd-20231231_htm.xml (XML) — 156KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 14 Item 1C. Cybersecurity 18 Item 2.

Properties

Properties 18 Item 3.

Legal Proceedings

Legal Proceedings 18 Item 4. Mine Safety Disclosure 18 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19 Item 6. [Reserved] 19 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 23 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 23 Item 9A.

Controls and Procedures

Controls and Procedures 23 Item 9B. Other Information 24 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 24 PART III Item 10. Directors, Executive Officers and Corporate Governance 24 Item 11.

Executive Compensation

Executive Compensation 26 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 27 Item 13. Certain Relationships and Related Transactions, and Director Independence 29 Item 14. Principal Accounting Fees and Services 30 PART IV Item 15. Exhibits, Financial Statement Schedules 30

Signatures

Signatures 32 4 PART I

BUSINESS

ITEM 1. BUSINESS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this Report constitute "forward-looking actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words "believe,""expect,""anticipate,""intend" and "plan" and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Corporate History NU-MED PLUS, INC., a Utah corporation ("NU-MED" or the "Company") was incorporated in October 2011 in the state of Utah to develop, manufacture and market new technologies utilizing nitric oxide in the medical device field, primarily through the creation of a nitric oxide generating compound formulation and delivery systems. To date we have developed a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for

Business

Business NU-MED was organized as a medical device company principally engaged in the design, innovation, development, enhancement and commercialization of beginning, early, and selective later-stage quality medical devices. The mission of NU-MED is to design, develop, and market technologies utilizing nitric oxide in the medical device field. Our technologies are focused on market niches in high growth trend areas. Our products are developed to target a current need in medical procedures by improving upon an existing technology or device or by designing a device to serve a currently unfilled need that is clearly defined and acknowledged by medical professionals. Our focus to date has been on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to the medical community throughout the world. Products Development of our products has been suspended until such time as a capital infusion is received which will enable the funding of further development. The following is a description of the medical application for the products that have been under development and the status of each of those products: Nitric oxide is an extremely important bio-mediator in the human body that is produced from the amino acid l-arginine. Nitric oxide has anti-inflammatory properties, antibacterial, antiviral and antifungal properties which make it useful in certain medical treatments. At the present time inhaled nitric oxide (INO ) is used as a selective vasodilator in infants. The only FDA approved use of nitric oxide at this time is for the treatment of Hypoxia in premature infants and newborn babies. Management is not aware of any other potential uses of nitric oxide that have been cleared by the FDA, but this may change as new submittals are made. The heavy cost of delivering nitric oxi

View Full Filing

View this 10-K filing on SEC EDGAR